Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China
· Delayed Price · Currency is CNY 36.60
-0.35 (-0.95%)
Mar 9, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Market Cap
Hangzhou Biotest Biotech has a market cap or net worth of 5.36 billion as of March 9, 2026. Its market cap has increased by 50.18% in one year.
Market Cap
5.36B
Enterprise Value
3.83B
Revenue
448.37M
Ranking
n/a
PE Ratio
114.38
Stock Price
36.60
Market Cap Chart
Since September 8, 2021, Hangzhou Biotest Biotech's market cap has decreased from 8.23B to 5.36B, a decrease of -34.91%. That is a compound annual growth rate of -9.11%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 5.41B | -2.20% |
| Dec 31, 2025 | 5.53B | 60.13% |
| Dec 31, 2024 | 3.45B | 6.92% |
| Dec 29, 2023 | 3.23B | -34.48% |
| Dec 30, 2022 | 4.93B | -33.91% |
| Dec 31, 2021 | 7.46B | -9.37% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Wuhan Hvsen Biotechnology | 5.25B |
| ChemPartner PharmaTech | 5.18B |
| PharmaResources (Shanghai) | 5.64B |
| Jiangsu Bioperfectus Technologies | 5.01B |
| Novogene | 5.84B |
| Shouyao Holdings (Beijing) Co., LTD. | 5.86B |
| Beijing Bohui Innovation Biotechnology Group | 4.96B |
| Kexing Biopharm | 5.97B |